Literature DB >> 20395438

The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin.

David Metalli1, Francesca Lovat, Farida Tripodi, Marco Genua, Shi-Qiong Xu, Michela Spinelli, Lilia Alberghina, Marco Vanoni, Raffaele Baffa, Leonard G Gomella, Renato V Iozzo, Andrea Morrione.   

Abstract

The insulin-like growth factor receptor I (IGF-IR) plays an essential role in transformation by promoting cell growth and protecting cancer cells from apoptosis. Aberrant IGF-IR signaling is implicated in several types of tumors, including carcinomas of the lung, breast, prostate, pancreas, liver, and colon. However, the contribution of the IGF-IR to the development of the transformed phenotype in urothelial cells has not been clearly established. In this study we demonstrated that the IGF-IR is overexpressed in invasive bladder cancer tissues compared with nonmalignant controls. We have investigated the role of the IGF-IR in bladder cancer by using urothelial carcinoma-derived 5637 and T24 cells. Although activation of the IGF-IR did not appreciably affect their growth, it did promote migration and stimulate in vitro wound closure and invasion. These effects required the activation of the Akt and Mitogen-activated protein kinase (MAPK) pathways as well as IGF-I-induced Akt- and MAPK-dependent phosphorylation of paxillin, which relocated at dynamic focal adhesions and was necessary for promoting motility in bladder cancer cells. Our results provide the first evidence for a role of the IGF-IR in motility and invasion of bladder cancer cells and support the hypothesis that the IGF-IR may play a critical role in the establishment of the invasive phenotype in urothelial neoplasia. Thus, the IGF-IR may also serve as a novel biomarker for bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20395438      PMCID: PMC2877859          DOI: 10.2353/ajpath.2010.090904

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

Review 1.  Differentiation and malignant transformation: two roads diverged in a wood.

Authors:  R Baserga; A Morrione
Journal:  J Cell Biochem       Date:  1999       Impact factor: 4.429

Review 2.  The role of the insulin-like growth factors in cancer.

Authors:  D Le Roith; M Karas; S Yakar; B H Qu; Y Wu; V A Blakesley
Journal:  Isr Med Assoc J       Date:  1999-09       Impact factor: 0.892

Review 3.  Regulation of proliferation and apoptosis by the insulin-like growth factor I receptor.

Authors:  D Le Roith
Journal:  Growth Horm IGF Res       Date:  2000-04       Impact factor: 2.372

4.  Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4.

Authors:  F Peruzzi; M Prisco; A Morrione; B Valentinis; R Baserga
Journal:  J Biol Chem       Date:  2001-05-14       Impact factor: 5.157

5.  Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.

Authors:  M Bartucci; C Morelli; L Mauro; S Andò; E Surmacz
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

6.  Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells.

Authors:  A Morrione; G Romano; M Navarro; K Reiss; B Valentinis; M Dews; E Eves; M R Rosner; R Baserga
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

Review 7.  The contradictions of the insulin-like growth factor 1 receptor.

Authors:  R Baserga
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

8.  Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis.

Authors:  Shuta Ishibe; Dominique Joly; Xiaolei Zhu; Lloyd G Cantley
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 10.  Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.

Authors:  Eva Surmacz
Journal:  Oncogene       Date:  2003-09-29       Impact factor: 9.867

View more
  45 in total

1.  Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.

Authors:  Jilong Yang; Antti Ylipää; Yan Sun; Hong Zheng; Kexin Chen; Matti Nykter; Jonathan Trent; Nancy Ratner; Dina C Lev; Wei Zhang
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

2.  Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.

Authors:  Haiping Zhou; Hong-ying Huang; Ellen Shapiro; Herbert Lepor; William C Huang; Moosa Mohammadi; Ian Mohr; Moon-shong Tang; Chuanshu Huang; Xue-ru Wu
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

3.  Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A.

Authors:  Alaide Morcavallo; Marco Genua; Angela Palummo; Emilia Kletvikova; Jiri Jiracek; Andrzej M Brzozowski; Renato V Iozzo; Antonino Belfiore; Andrea Morrione
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

Review 4.  Decoding the Matrix: Instructive Roles of Proteoglycan Receptors.

Authors:  Thomas Neill; Liliana Schaefer; Renato V Iozzo
Journal:  Biochemistry       Date:  2015-07-22       Impact factor: 3.162

Review 5.  Significance of talin in cancer progression and metastasis.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

Review 6.  Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology.

Authors:  Madalina V Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Biochim Biophys Acta       Date:  2014-02-05

7.  Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Authors:  Paul Haluska; Michael Menefee; Elizabeth R Plimack; Jonathan Rosenberg; Donald Northfelt; Theresa LaVallee; Li Shi; Xiang-Qing Yu; Patricia Burke; Jiaqi Huang; Jaiqi Huang; Jaye Viner; Jennifer McDevitt; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2014-07-14       Impact factor: 12.531

8.  PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex.

Authors:  David de Semir; Vladimir Bezrookove; Mehdi Nosrati; Kara R Scanlon; Eric Singer; Jonathon Judkins; Christopher Rieken; Clayton Wu; Julia Shen; Christina Schmudermayer; Altaf A Dar; James R Miller; Charles Cobbs; Garret Yount; Pierre-Yves Desprez; Robert J Debs; Nathan Salomonis; Sean McAllister; James E Cleaver; Liliana Soroceanu; Mohammed Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-09       Impact factor: 11.205

Review 9.  Insulin-like growth factor system and sporadic malignant melanoma.

Authors:  Ettore Capoluongo
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 10.  Dichotomy of decorin activity on the insulin-like growth factor-I system.

Authors:  Andrea Morrione; Thomas Neill; Renato V Iozzo
Journal:  FEBS J       Date:  2013-02-15       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.